Literature DB >> 15885602

C-reactive protein and NT-proBNP as surrogate markers for pulmonary hypertension in Gaucher disease.

Deborah Elstein1, Amiram Nir, Marc Klutstein, Bernard Rudensky, Ari Zimran.   

Abstract

BACKGROUND: N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) values correlate with mild-moderate pulmonary hypertension assessed by tricuspid insufficiency (TI) gradient>or=30 mm Hg in Gaucher disease. The purpose of this study is to ascertain improved risk stratification based on correlation with NT-proBNP and C-reactive protein (CRP), a standard marker of inflammation.
METHODS: Patients with type I Gaucher disease were selected to reflect differing degrees of echocardiographically determined TI gradient values. NT-proBNP was performed by immunoassay and CRP by standard methods.
FINDINGS: There were 45 patients (18 males; 40%); mean age=42.5 (range: 4-80) years. Median NT-proBNP value=153 (range: 46-6703) pg/ml; median CRP value=0.145 (range: 0.02-2.69) mg/dl. There was a statistically significant correlation between these values (r=0.445, P<0.01). Elevations of CRP and NT-proBNP were risk factors for pulmonary hypertension with odds ratios of 8.47 and 4.9, respectively. The area under the Receiving Operator Characteristic (ROC) curve for diagnosis of pulmonary hypertension was 0.93+/-0.04 for CRP, and 0.7+/-0.1 for NT-proBNP. All patients with pulmonary hypertension had elevation of either CRP or NT-proBNP (100% sensitivity).
CONCLUSIONS: Elevated CRP was a better predictor of pulmonary hypertension in Gaucher disease than elevated NT-proBNP values. Elevated CRP (>0.5 mg/dl) or elevated NT-proBNP (>150 pg/ml) reduces the need to perform echocardiography by more than half, even in this group with over-representation of pulmonary hypertension. The role of inflammatory features in pulmonary hypertension in Gaucher disease is discussed. Further studies are required to ascertain if this approach is useful for prognosis of pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885602     DOI: 10.1016/j.bcmd.2005.01.002

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease.

Authors:  G Altarescu; G Chicco; C Whybra; S Delgado-Sanchez; N Sharon; M Beck; D Elstein
Journal:  J Inherit Metab Dis       Date:  2008-01-05       Impact factor: 4.982

2.  High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus.

Authors:  Shin-Seok Lee; Sukhminder Singh; Kimberly Link; Michelle Petri
Journal:  Semin Arthritis Rheum       Date:  2008-01-25       Impact factor: 5.532

3.  Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia.

Authors:  Steve D Swain; Soo Han; Ann Harmsen; Katie Shampeny; Allen G Harmsen
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

4.  Abnormal nonstoring capillary endothelium: a novel feature of Gaucher disease. Ultrastructural study of dermal capillaries.

Authors:  Helena Hůlková; Helena Poupetová; Klaus Harzer; Pramod Mistry; Johannes M F G Aerts; Milan Elleder
Journal:  J Inherit Metab Dis       Date:  2010-01-05       Impact factor: 4.982

5.  Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension.

Authors:  Rajeev Malhotra; Samuel Paskin-Flerlage; Roham T Zamanian; Patrick Zimmerman; Jonathan W Schmidt; Donna Y Deng; Mark Southwood; Robert Spencer; Carol S Lai; William Parker; Richard N Channick; Nicholas W Morrell; C Gregory Elliott; Paul B Yu
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

6.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension.

Authors:  Omar A Minai
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.